Sunshine Biopharma(SBFM) - 2023 Q4 - Annual Results

Financial Performance - Sunshine Biopharma, Inc. reported financial results for the year ended December 31, 2023, with total revenue of $5 million, representing a 25$2 million for the same period, which is a 15% improvement from the net loss of $2.35 million in 2022[5] - Sunshine Biopharma's cash and cash equivalents at the end of 2023 were$3 million, up from $1.5 million at the end of 2022, indicating a 100$1 million in R&D for 2024[5] - Sunshine Biopharma anticipates revenue growth of 30% for the fiscal year 2024, driven by increased market demand and new product launches[5] - The company is exploring potential strategic partnerships to enhance its market presence and accelerate product development[5] - Sunshine Biopharma is also considering acquisitions to expand its portfolio and strengthen its competitive position in the biopharmaceutical market[5] Patient Engagement and Innovation - The company reported an increase in user data, with a 40% rise in the number of active patients using its therapies compared to the previous year[5] - Sunshine Biopharma's management emphasized a commitment to innovation and improving patient outcomes through advanced biopharmaceutical solutions[5] Operational Efficiency - The company is focused on enhancing its operational efficiency to reduce costs and improve overall profitability in the coming years[5]